FDA Approves RYBREVANT FASPRO™ for Quick, First-Line Lung Cancer Treatment
The FDA approved RYBREVANT FASPRO™, a subcutaneous therapy for EGFR-mutated NSCLC, offering faster, more convenient treatment with fewer reactions compared to IV, and demonstrating improved survival outcomes when combined with LAZCLUZE® in first-line treatment.